Literature DB >> 31154574

CNS-Specific Synthesis of Interleukin 23 Induces a Progressive Cerebellar Ataxia and the Accumulation of Both T and B Cells in the Brain: Characterization of a Novel Transgenic Mouse Model.

Louisa Nitsch1, Julian Zimmermann1, Marius Krauthausen1, Markus J Hofer2, Raman Saggu3, Gabor C Petzold1,3, Michael T Heneka1,4, Daniel R Getts5, Albert Becker6, Iain L Campbell7, Marcus Müller8,9.   

Abstract

Interleukin 23 (IL-23) is a key mediator in neuroinflammation in numerous autoimmune diseases including multiple sclerosis (MS). However, the pathophysiology of IL-23 and how it contributes to neuroinflammation is poorly defined. To further clarify the role of IL-23 in CNS inflammation, we generated a transgenic mouse model (GF-IL23) with astrocyte-targeted expression of both IL-23 subunits, IL-23p19, and IL-23p40. These GF-IL23 mice spontaneously develop a progressive ataxic phenotype, which corresponds to cerebellar tissue destruction, and inflammatory infiltrates most prominent in the subarachnoidal and perivascular space. The CNS-cytokine milieu was characterized by numerous inflammatory mediators such as IL-17a and IFNγ. However, the leukocytic infiltrates were surprisingly predominated by B cells. To further examine the impact of the CNS-specific IL-23 synthesis on an additional systemic inflammatory stimulus, we applied the LPS-induced endotoxemia model. Administration of LPS in GF-IL23 mice resulted in early and pronounced microglial activation, enhanced cytokine production and, in sharp contrast to control animals, in the formation of lymphocytic infiltrates. Our model confirms a critical role for IL-23 in the induction of inflammation in the CNS, in particular facilitating the accumulation of lymphocytes in and around the brain. Thereby, CNS-specific synthesis of IL-23 is able to induce a cascade of inflammatory cytokines leading to microglia activation, astrocytosis, and ultimately tissue damage. The presented transgenic model will be a useful tool to further dissect the role of IL-23 in neuroinflammation.

Entities:  

Keywords:  Autoimmunity; B cells; CNS; IL-23; LPS; Neuroinflammation

Mesh:

Substances:

Year:  2019        PMID: 31154574     DOI: 10.1007/s12035-019-1640-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  66 in total

1.  An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis.

Authors:  Mohammad Reza Javan; Sarieh Shahraki; Amin Safa; Mohammad Reza Zamani; Arash Salmaninejad; Saeed Aslani
Journal:  Neurol Res       Date:  2017-03-09       Impact factor: 2.448

2.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.

Authors:  Christi Parham; Madaline Chirica; Jacqueline Timans; Elena Vaisberg; Marilyn Travis; Jeanne Cheung; Stefan Pflanz; Rebecca Zhang; Komal P Singh; Felix Vega; Wayne To; Janet Wagner; Anne-Marie O'Farrell; Terrill McClanahan; Sandra Zurawski; Charles Hannum; Daniel Gorman; Donna M Rennick; Robert A Kastelein; Rene de Waal Malefyt; Kevin W Moore
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

4.  Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis.

Authors:  Albert Quintana; Marcus Müller; Ricardo F Frausto; Raquel Ramos; Daniel R Getts; Elisenda Sanz; Markus J Hofer; Marius Krauthausen; Nicholas J C King; Juan Hidalgo; Iain L Campbell
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

5.  IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice.

Authors:  Stefan Haak; Andrew L Croxford; Katharina Kreymborg; Frank L Heppner; Sandrine Pouly; Burkhard Becher; Ari Waisman
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

6.  Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.

Authors:  Terrence Town; Fengwei Bai; Tian Wang; Amber T Kaplan; Feng Qian; Ruth R Montgomery; John F Anderson; Richard A Flavell; Erol Fikrig
Journal:  Immunity       Date:  2009-02-05       Impact factor: 31.745

7.  Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.

Authors:  Johannes Vom Berg; Stefan Prokop; Kelly R Miller; Juliane Obst; Roland E Kälin; Ileana Lopategui-Cabezas; Anja Wegner; Florian Mair; Carola G Schipke; Oliver Peters; York Winter; Burkhard Becher; Frank L Heppner
Journal:  Nat Med       Date:  2012-11-25       Impact factor: 53.440

8.  Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration.

Authors:  Jacque P K Ip; Aline L Noçon; Markus J Hofer; Sue Ling Lim; Marcus Müller; Iain L Campbell
Journal:  J Neuroinflammation       Date:  2011-09-26       Impact factor: 8.322

9.  Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease.

Authors:  René Pfeifle; Tobias Rothe; Natacha Ipseiz; Hans U Scherer; Stephan Culemann; Ulrike Harre; Jochen A Ackermann; Martina Seefried; Arnd Kleyer; Stefan Uderhardt; Benjamin Haugg; Axel J Hueber; Patrick Daum; Gordon F Heidkamp; Changrong Ge; Sybille Böhm; Anja Lux; Wolfgang Schuh; Iryna Magorivska; Kutty S Nandakumar; Erik Lönnblom; Christoph Becker; Diana Dudziak; Manfred Wuhrer; Yoann Rombouts; Carolien A Koeleman; René Toes; Thomas H Winkler; Rikard Holmdahl; Martin Herrmann; Stephan Blüml; Falk Nimmerjahn; Georg Schett; Gerhard Krönke
Journal:  Nat Immunol       Date:  2016-11-07       Impact factor: 25.606

10.  Imbalance between IL-17A-producing cells and regulatory T cells during ischemic stroke.

Authors:  Yuehua Hu; Yanhua Zheng; Ya Wu; Bing Ni; Shugui Shi
Journal:  Mediators Inflamm       Date:  2014-06-01       Impact factor: 4.711

View more
  5 in total

1.  MOG-Specific T Cells Lead to Spontaneous EAE with Multilocular B Cell Infiltration in the GF-IL23 Model.

Authors:  Louisa Nitsch; Simon Petzinna; Julian Zimmermann; Daniel R Getts; Albert Becker; Marcus Müller
Journal:  Neuromolecular Med       Date:  2022-03-03       Impact factor: 3.843

Review 2.  Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?

Authors:  Rohit Kumar Tiwari; Afrasim Moin; Syed Mohd Danish Rizvi; Syed Monowar Alam Shahid; Preeti Bajpai
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

3.  Astrocyte-specific expression of interleukin 23 leads to an aggravated phenotype and enhanced inflammatory response with B cell accumulation in the EAE model.

Authors:  Louisa Nitsch; Simon Petzinna; Julian Zimmermann; Linda Schneider; Marius Krauthausen; Michael T Heneka; Daniel R Getts; Albert Becker; Marcus Müller
Journal:  J Neuroinflammation       Date:  2021-04-27       Impact factor: 8.322

4.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

5.  Neuroinflammatory transcriptional programs induced in rhesus pre-frontal cortex white matter during acute SHIV infection.

Authors:  Chase E Hawes; Sonny R Elizaldi; Danielle Beckman; Giovanne B Diniz; Yashavanth Shaan Lakshmanappa; Sean Ott; Blythe P Durbin-Johnson; Ashok R Dinasarapu; Andrea Gompers; John H Morrison; Smita S Iyer
Journal:  J Neuroinflammation       Date:  2022-10-06       Impact factor: 9.587

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.